The Prognostic Impact of <i>HMGCLL1</i> Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Perusini, María Agustina; Kim, Taehyung Simon; Žáčková, Daniela; Pagnano, Katia B; Mayer, Jiří; Pavlovsky, Carolina; Ježíšková, Ivana; Kvetková, Anežka; Jurček, Tomáš; Moiraghi, Beatriz; Varela, Ana Inés; Bianchini, Michele; Lopes, Ana Beatriz Pascoal; Duarte, Graciana Alves; Yoo, Young Seok; Souza, Cármino Antonio De; Medeiros, Jessie J. F.; Lee, Hye Won; Kim, Kyoung Ha; Yi, Seong Yoon; Chang, Myung Hee; Abelson, Sagi; Kim, Dennis Dong Hwan

doi:10.1182/blood-2022-168228

Blood

2022

DOI: 10.1182/blood-2022-168228

|View full text |Cite

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

María Agustina Perusini

Taehyung Simon Kim

Daniela Žáčková

et al.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

This publication either has no citations yet, or we are still processing them

See others like this or search for similar articles

Contact Info

Product

Resources

About